Biomedical Engineering Reference
In-Depth Information
16. Whittle IR. (2002) Surgery for gliomas. Curr. Opin. Neurol. 5,
663-669.
17. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B,
Taphoorn MJ, et al. (2005) Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352,
987-996.
18. Pastan I, Chaudhary VK, Fitzgerald DJ. (1992) Recombinant
toxins as novel therapeutic agents. Annu. Rev. Biochem. 61,
331-354.
19. Pastan I, Fitzgerald D. (1992) Recombinant toxins for cancer
treatment. Science 254, 1173-1177.
20. Husain SR, Puri RK. (2003) Interleukin-13 receptor-directed
cytotoxin for malignant glioma therapy: from bench to bed-
side. J. Neurooncol. 65, 37-48.
21. Hall WA, Fodstad O. (1992) Immunotoxins and central ner-
vous system neoplasia. J. Neurosurg. 76, 1-12.
22. Gottstein C, Winkler U, Bohlen H, Diehl V, Engert A. (1994)
Immunotoxins: is there a clinical value? Ann. Oncol. 5(Suppl. 1),
97-103.
23. Puri RK, Siegel JP. (1993) Interleukin-4 and cancer therapy.
Cancer Invest . 11, 473-486.
24. Reiter Y. (2001) Recombinant immunotoxins in targeted can-
cer cell therapy. Adv. Cancer Res. 81, 93-124.
25. Chiocca EA, Broaddus WC, Gillies GT, Visted T, Lamfers ML.
(2004) Neurosurgical delivery of chemotherapeutics, targeted
toxins, genetic and viral therapies in neuro-oncology. J. Neuro-
oncol. 69, 101-117.
26. Weaver M, Laske DW. (2003) Transferrin receptor ligand-
targeted toxin conjugate (Tf-CRM107) for therapy of malig-
nant gliomas. J. Neurooncol. 65, 3-13.
27. Rustamzadeh E, Low WC, Vallera DA, Hall WA. (2003)
Immunotoxin
tumors in a mouse model [Abstract]. Proc. Am. Assoc. Cancer
Res. 45, 5402.
34. Kreitman RJ, Puri PK, Pastan I. (1994) A circularly permuted
recombinant interleukin 4 toxin with increased activity. Proc.
Natl. Acad. Sci. USA 91, 6889-6893.
35. Kreitman RJ, Puri RK, Pastan I. (1995) Increased antitumor
activity of a circularly permuted IL-4-toxin in mice with IL-4
receptor bearing human carcinoma. Cancer Res. 55, 3357-3363.
36. Frankel AE, Kreitman RJ, Sausville EA. (2000) Targeted
toxins. Clin. Cancer Res. 6, 326-334.
37. Puri RK, H oo n DS, Leland P, Snoy P, Rand RW, Pastan I ,
et al. (1996) Preclinical d evel o p m e nt o f a r e c o m b i n a nt t ox i n
containing circul arly pe rmuted interleukin 4 and trunc a ted
Pseudomona s exotox in for therapy of malignant astrocy-
toma. Cancer Res . 56, 5631-56 37.
38. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. (1999)
The IL-4 receptor: signaling mechanisms and biologic func-
tions. Ann. Rev. Immunol. 17, 701-738.
39. Kruse N, Shen B, Arnold S, Tony HP, Muller T, Sebald W.
(1993) Two distinct functional sites of human interleukin 4 are
identified by variants impaired in either receptor binding or
receptor activation. EMBO J. 12, 5121-5129.
40. Muller T, Dieckmann T, Sebald W, Oschkinat H. (1994)
Aspects of receptor binding and signalling of interleukin-4
investigated by site-directed mutagenesis and NMR spectros-
copy. J. Mol. Biol. 237, 423-436.
41. Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. (1995)
Human glioma cells overexpress receptors for interleukin 13
and are extremely sensitive to a novel chimeric protein com-
posed of interleukin 13 and Pseudomonas exotoxin. Clin.
Cancer Res. 1, 1253-1258.
42. Joshi BH, Plautz, GE, Puri RK. (2000) Interleukin-13 receptor
alpha chain: a novel tumor-associated transmembrane protein
in primary explants of human malignant gliomas. Cancer Res.
60, 1168-1172.
43. Joshi BH, Leland P, Asher A, Prayson RA, Varricchio F, Puri
RK. (2001) In situ expression of Interleukin-4 receptors in
human brain tumors and cytotoxicity of a recombinant inter-
leukin-4 (IL-4) cytotoxin in primary glioblastoma cell cultures.
Cancer Res. 61, 8058-8061.
44. Husain SR, Behari N, Kreitman RJ, Pastan I, Puri RK. (1998)
Complete regression of established human glioblastoma tumor
xenograft by interleukin-4 toxin therapy. Cancer Res. 58,
3649-3653.
45. Weber F, Asher A, Bucholz R, Berger M, Prados M, Chang S,
et al. (2003) Safety, tolerability, and tumor response of IL4-
Pseudomonas exotoxin (NBI-3001) in patients with recurrent
malignant glioma. J. Neurooncol. 64, 125-137.
46. http://clinicaltrials.gov, study identifier NCT00014677. Last
accessed on Oct. 28th, 2012.
47. Hunter T. (1984) The epidermal growth factor receptor gene
and its product. Nature 311, 414-416.
48. Liberman TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H,
et al. (1985) Amplification, enhanced expression, and possible
rearrangement of EGF receptor gene in primary human brain
tumors of glial origin. Nature 313, 144-147.
therapy for CNS
tumor. J. Neurooncol. 64,
101-116.
28. Baxter LT, Jain RK. (1989) Transport of fluid and macro-
molecules in tumors I. Role of interstitial pressure and con-
vection. Microvasc. Res. 37, 77-102.
29. Morrison PF, Laske DW, Bobo H, Oldfield EH, Dedrick RL.
(1994) High-flow microinfusion: tissue penetration and phar-
macodynamics. Am. J. Physiol. 266, R292-305.
30. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL,
Oldfield EH. (1994) Convection-enhanced delivery of macro-
molecules in the brain. Proc. Natl. Acad. Sci. USA 91, 2076-
2080.
31. Laske DW, Morrison PF, Lieberman DM, Corthesy ME,
Reynolds JC, Stewart-Henney PA, et al. (1997) Chronic inter-
stitial infusion of protein to primate brain: determination of
drug distribution and clearance with single-photon emission
computerized tomography imaging. J. Neurosurg. 87, 586-
594.
32. Baxter LT, Jain RK. (1989) Transport of fluid and macro-
molecules in tumors I. Role of interstitial pressure and con-
vection. Microvasc. Res. 37, 77-102.
33. Kawakami K, Kawakami M, Kioi M, Husain SR, Puri RK.
(2004) Distribution of bolus or convection-enhanced delivery
of IL-13 receptor-directed cytotoxin
to
intracranial brain
Search WWH ::
Custom Search